Pasireotide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Pasireotide
Pasireotide.svg
Clinical data
Trade names Signifor
License data
Routes of
administration
Subcutaneous
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
Synonyms SOM230
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ECHA InfoCard 100.211.883
Chemical and physical data
Formula C58H66N10O9
Molar mass 1047.21 g/mol[1]
3D model (JSmol)
 NYesY (what is this?)  (verify)

Pasireotide (SOM230, trade name Signifor[2]) is an orphan drug approved in the United States[3] and Europe[4] for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy.[5][6] It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.

Pasireotide was approved for Cushing's disease by the EMEA in October 2009[7] and by the FDA in December 2012.[8]

Pasireotide LAR was approved by the FDA for treatment of acromegaly in December 2014, and had been approved for this indication by the EMEA one month earlier.[9]

References[edit]